Introduction
============

Vogt-Koyanagi-Harada (VKH) disease is one of the most frequent forms of uveitis in Japan \[[@r1]\]. It is characterized as bilateral panuveitis accompanied by neurologic and skin lesions \[[@r2],[@r3]\]. This disease is considered to be an autoimmune disease against melanocytes \[[@r4],[@r5]\]. Though the etiology of VKH disease still remains unknown, genetic factors may play an important role in susceptibility as indicated by an established association between VKH disease and specific human leukocyte antigen (*HLA*)*-DRB1* alleles \[[@r6],[@r7]\].

The protein tyrosine phosphatase non-receptor 22 gene (*PTPN22*) is located on chromosome 1p13.3-p13.1, and it encodes the lymphoid-specific phosphatase (Lyp) that is important in the negative control of T-cell activation and development \[[@r8]-[@r10]\]. Recently, it was reported the single nucleotide polymorphism (SNP), R620W ([rs2476601](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2476601)), in *PTPN22* increased susceptibility to several autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and insulin dependent diabetes mellitus (IDDM) \[[@r11]-[@r15]\]. In the *PTPN22* risk variant ([rs2476601](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2476601)), this substitution disrupts an interaction between Lyp and the protein tyrosine kinase, Csk, and may translate biologically to a potential for 'hyperreactive' pathogenic T-cell responses \[[@r8]\].

This R620W mutation was not observed in the Japanese population \[[@r16],[@r17]\]. Therefore, in this study, we analyzed six SNPs, which belong to the same haplotype block as R620W ([rs2476601](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2476601)) in *PTPN22*. For the efficacy of the linkage analysis, we chose six SNPs of which minor allele frequencies were more than 15% from the database of [Japanese Single Nucleotide Polymorphisms](http://snp.ims.u-tokyo.ac.jp/) \[[@r18],[@r19]\].

Methods
=======

We recruited 167 VKH (72 males and 95 females) patients and 188 healthy controls for this study. All patients and control subjects were Japanese. Patients were diagnosed according to the "Revised Diagnostic Criteria for VKH Disease" \[[@r3]\] at the Uveitis Survey Clinic of the Hokkaido University Hospital (Sapporo, Japan) and Yokohama City University Hospital (Yokohama, Japan). All patients and control subjects were informed of the study's purpose, and their consent obtained. The study was approved by the ethics committee from each institute participating in this study.

DNA was prepared from peripheral blood specimens using the QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan). Six SNPs ([rs3811021](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3811021), [rs1217413](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1217413), [rs1237682](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1237682), [rs3761935](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3761935), [rs3789608](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3789608), and [rs2243471](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2243471)) from the *PTPN22* region were examined ([Figure 1](#f1){ref-type="fig"}). Each of the six SNPs was amplified by standard polymerase chain reactions (PCRs; [Table 1](#t1){ref-type="table"}). After purification using ExoSAP-IT (USB Corporation, Cleveland, OH), the PCR products were sequenced with Big Dye Terminator v3.1 (Applied Biosystems, Foster City, CA) using either sense or antisense primers ([Table 1](#t1){ref-type="table"}). The BigDye XTerminator Purification Kit (Applied Biosystems) was used to purify the DNA from sequencing reactions. The sequencing reactions were analyzed using an ABI3130 sequencer (Applied Biosystems).

![*PTPN22* structure with two transcript isoforms and six SNP. Six SNP variants with minor allele frequencies 15% from the database of [Japanese Single Nucleotide Polymorphisms](http://snp.ims.u-tokyo.ac.jp/). The black and white areas in the exons indicate the UTR and coding region, respectively.](mv-v15-1115-f1){#f1}

###### PCR primers for *PTPN22* SNPs.

  **SNP**                                                                                    **position**   **Primers**                  **Product size (bp)**   **sequence primer**
  --------------------------------------------------------------------------------- -------- -------------- ---------------------------- ----------------------- ---------------------
  [rs3811021](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3811021)               (SNP1)   114158186      F: TGGGTTGCAATACAAACTGCTC    600                     Forward
  R: TCAATTTGCCCTATTGGACTTC                                                                                                                                      
  [rs1217413](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1217413)               (SNP2)   114159273      F: TTGCAGGTGTACTTGCAGCC      552                     Forward
  R: TTGAAGGATTTCTGGACCGAC                                                                                                                                       
  [rs1237682](~WRL0620.tmphttp://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1237682)   (SNP3)   114165627      F: AAGGAGGCACAGATTCCACAC     589                     Forward
  R: TGACCATGCCAATATACCAACTG                                                                                                                                     
  [rs3761935](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3761935)               (SNP4)   114174051      F: AAAGTTTCCGGCATGTTTCC      595                     Reverse
  R: TGGTGATTGTCGGCTAAGATTG                                                                                                                                      
  [rs3789608](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3789608)               (SNP5)   114199311      F: CATCATGGTCTGGCCAATTC      589                     Forward
  R: TGAGGTGGAGTTCTAACCACAAG                                                                                                                                     
  [rs2243471](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2243471)               (SNP6)   114207525      F: GACAAGACTGAATTGTACGAGCG   577                     Forward
  R: CACCATCTCCAGCCTCTCAC                                                                                                                                        

The position of the SNPs is cited from the NCBI database.

Statistical analysis
--------------------

For statistical analyses, the Hardy--Weinberg equilibrium was tested for each SNP among the control subjects. Genotype frequency differences between the case and control genotypes were assessed by the χ^2^ test. The calculation of linkage disequilibrium (LD) and pair-wise LD (D' value) between SNPs of the *PTPN22* region and the haplotypes was performed with [Haploview](http://www.broad.mit.edu/mpg/haploview/) software, version 3.32. The maximum likelihood estimates of haplotype frequencies were estimated by pairs of unphased genotypes using the expectation-maximization (EM) algorithms in the R package '[haplo.stats](http://mayoresearch.mayo.edu/mayo/research/schaid_lab/software.cfm)' \[[@r20]\].

Results
=======

Allele frequencies for the six SNPs covering the gene were in Hardy--Weinberg equilibrium in both the patients and controls. The allelic frequency of each SNP in both groups was nearly equal, and no association was detected when compared independently (odds ratio, OR 1.14--1.35; [Table 2](#t2){ref-type="table"}). Stratifying the patients by the presence of diffuse choroiditis, sunset glow fundus, nummular chorioretinal depigmented spots, neurologic auditory involvement, meningismus, tinnitus, cerebrospinal fluid pleocytosis, or integumentary findings also revealed no evidence of association in VKH disease (data not shown). We calculated pairwise D' values for all SNP pairs in *PTPN22* ([Figure 2](#f2){ref-type="fig"}). The pairwise D' values in the gene were nearly 1 among almost all SNP pairs, indicating the SNPs were highly associated with each other and the entire *PTPN22* was contained within a single LD block. Haplotype analysis predicted and revealed that *PTPN22* was not associated with VKH disease in this Japanese cohort (data not shown).

###### Genotype frequencies in VKH patients and controls.

  **SNP**                                                               **Allele**   **VKH (n=168)**   **Percentage**   **Control (n=187)**   **Percentage**      **Odds ratio (95% CI)**   **p**
  --------------------------------------------------------------------- ------------ ----------------- ---------------- --------------------- ------------------- ------------------------- -------
  [rs3811021](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3811021)   C/C          2                 1.2              9                     4.8                 0.24 (0.05--17.47)        0.05
  T/C                                                                   56           33.5              67               35.8                  0.90 (0.58--7.38)   0.65                      
  T/T                                                                   109          65.3              111              59.4                  1.29 (0.84--7.53)   0.25                      
  C                                                                     60                             85                                     0.75 (0.51--7.41)   0.12                      
  [rs1217413](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1217413)   A/A          26                16               36                    19.4                0.79 (0.45--7.63)         0.41
  A/G                                                                   77           47.2              91               48.9                  0.93 (0.61--7.43)   0.75                      
  G/G                                                                   60           36.8              59               31.7                  1.25 (0.80--7.56)   0.32                      
  A                                                                     129                            163                                    0.84 (0.62--7.25)   0.26                      
  [rs1237682](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1237682)   C/C          26                15.5             33                    18.4                0.83 (0.47--7.63)         0.53
  T/C                                                                   79           47                89               49.7                  0.94 (0.62--7.34)   0.77                      
  T/T                                                                   59           35.1              57               31.8                  1.20 (0.77--7.53)   0.42                      
  C                                                                     131                            155                                    0.87 (0.64--7.24)   0.37                      
  [rs3761935](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3761935)   G/G          3                 1.8              10                    5.3                 0.33 (0.09--12.76)        0.08
  T/G                                                                   55           33.3              67               35.8                  0.90 (0.58--7.39)   0.62                      
  T/T                                                                   107          64.8              110              58.8                  1.29 (0.84--7.54)   0.25                      
  G                                                                     61                             87                                     0.75 (0.52--7.41)   0.12                      
  [rs3789608](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3789608)   T/T          2                 1.2              9                     4.8                 0.24 (0.05--17.57)        0.05
  C/T                                                                   57           34.1              68               36.4                  0.91 (0.59--7.38)   0.66                      
  C/C                                                                   108          64.7              110              58.8                  1.26 (0.82--7.50)   0.29                      
  T                                                                     61                             86                                     0.74 (0.51--7.41)   0.11                      
  [rs2243471](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2243471)   A/A          27                16.7             37                    20.2                0.79 (0.46--7.62)         0.4
  A/G                                                                   79           48.8              88               48.1                  1.03 (0.67--7.36)   0.9                       
  G/G                                                                   56           34.6              58               31.7                  1.14 (0.73--7.48)   0.57                      
  A                                                                     133                            162                                    0.88 (0.65--7.24)   0.39                      

The above table is the genotype and allele frequencies of the VKH patients and healthy controls. There are no differences between patients and controls.

![D\' score for the six SNPs studied across the *PTPN22* haplotype. Black cells indicate that D\' is greater than 0.9. Upper: patient population, lower: control population. The figure indicates that the six SNPs were in all the same haplotype block.](mv-v15-1115-f2){#f2}

Discussion
==========

In the present study, we analyzed polymorphisms of the new candidate gene, *PTPN22*, in Japanese patients with VKH disease. The gene encodes an important negative regulator of T cell activation \[[@r9]\]. An SNP of *PTPN22*, R620W ([rs2476601](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2476601)) was reported to be associated with several autoimmune diseases such as RA, SLE, and IDDM \[[@r11],[@r12],[@r14],[@r15]\]. However, this SNP, which disrupts an interaction between Lyp and the protein tyrosine kinase, Csk, does not exist as a polymorphism in the Japanese population \[[@r9],[@r10],[@r12]\]. Therefore, in this study, we examined six other SNPs to evaluate the susceptibility locus of *PTPN22*. *HLA-DRB1* is a common genetic factor in autoimmune diseases (RA and IDDM). Therefore, there may be other common genetic factors in VKH disease \[[@r21]\].

VKH disease is considered to be an autoimmune disease against melanocytes \[[@r2]-[@r5]\]. In early studies, activated T lymphocytes were elevated and attacked melanocytes of ocular choroidal tissue in patients in the active phase of VKH disease \[[@r22]\]. Antigen-specific T-cell assay revealed that peptide fragments of the tyrosinase family proteins (tyrosinase, tyrosinase related protein 1 and 2) proliferated in T lymphocytes collected from VKH patients \[[@r4],[@r5]\]. These proteins are found in human melanocytes. These antigen-specific T cell responses were detected in cells collected from *HLA-DRB1\*04* positive VKH patients only but not from *HLA-DRB1\*04* negative patients or *HLA-DRB1\*04* positive healthy people \[[@r7],[@r23]\]. In the Japanese population, 40% of healthy people have *HLA-DRB1\*04* \[[@r7]\]. However, people having VKH disease represent only 0.01% of the Japanese population \[[@r1],[@r7],[@r24],[@r25]\]. In addition, some patients with VKH disease are *HLA-DRB1\*04* negative \[[@r7]\]. Thus, it is believed *HLA-DRB1\*04* is a major susceptible gene in VKH disease. However, other minor genetic factors still remain unclear. To find other susceptible genes, we studied the tyrosinase gene (*TYR*), tyrosinase related protein 1 gene (*TYRP1*), tyrosinase related protein 2 gene (*TYRP2*), and interferon (*IFN-γ*), but we could not find any association with these genes and VKH disease \[[@r7],[@r26]\]. Genetic influences of VKH were also investigated in other countries, but the etiology of the disease seems to be unresolved \[[@r27]-[@r29]\].

In this study, we found no association between *PTPN22* and VKH disease in the individuals studied. Our results suggest that further molecular genetic studies are needed to detect novel genetic loci and predisposing genes and to elucidate the true genetic mechanisms underlying VKH disease.
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